GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (BSP:A1RG34) » Definitions » Long-Term Debt

argenx SE (BSP:A1RG34) Long-Term Debt : R$0 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is argenx SE Long-Term Debt?

argenx SE's Long-Term Debt for the quarter that ended in Dec. 2024 was R$0 Mil.

argenx SE Long-Term Debt Historical Data

The historical data trend for argenx SE's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Long-Term Debt Chart

argenx SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

argenx SE Quarterly Data
Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

argenx SE  (BSP:A1RG34) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

argenx SE Long-Term Debt Related Terms

Thank you for viewing the detailed overview of argenx SE's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (BSP:A1RG34) » Definitions » Long-Term Debt
Comparable Companies
XBRU:UCB XBRU:TUB XBRU:ONWD XBRU:HYL XBRU:ALEMS XBRU:BIOS XBRU:OXUR VRTX ASX:CSL REGN XKRX:207940 ALNY ONC BNTX XKRX:068270 SMMT UTHR INSM XKRX:196170 RPRX
Traded in Other Exchanges
ARGX:USA ARGNF:USA ARGXb:UK 0QW0:UK 1AEA:Germany ARGX:Belgium ARGX:Austria
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Website
https://www.argenx.com
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines